stockportfolio.pro
Kestra Medical Technologies, Ltd. (KMTS)
Healthcare · Medical Instruments & Supplies · NasdaqGS
Kestra Medical Technologies, Ltd. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $7.63M | $27.81M | $59.81M |
| Gross profit | $-10.65M | $362,000 | $24.21M |
| Net income | $-84.24M | $-94.12M | $-113.81M |
| Net margin | -1104.0% | -338.4% | -190.3% |
Source: Kestra Medical Technologies, Ltd. SEC filings (10-K).
Explore 3 years of Kestra Medical Technologies, Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KMTS in your portfolio →
Kestra Medical Technologies, Ltd. financial history by metric
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Kestra Medical Technologies, Ltd. — frequently asked questions
What is Kestra Medical Technologies, Ltd.'s revenue?
Kestra Medical Technologies, Ltd. (KMTS) reported revenue of $59.81M for fiscal year 2025, up 115.1% from the prior year, according to its SEC filings.
Is Kestra Medical Technologies, Ltd. profitable?
No — KMTS reported a net loss of $-113.81M in fiscal 2025.
What is KMTS's P/E ratio?
Kestra Medical Technologies, Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Kestra Medical Technologies, Ltd. growing?
KMTS's revenue grew at roughly 180.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Kestra Medical Technologies, Ltd. have?
As of fiscal year 2025, KMTS carried roughly $41.10M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kestra Medical Technologies, Ltd.'s gross margin?
KMTS's gross margin was 40.5% in fiscal 2025 — gross profit of $24.21M on revenue of $59.81M.
What is Kestra Medical Technologies, Ltd.'s market cap?
Kestra Medical Technologies, Ltd. (KMTS) has a market capitalization of about $1.16B, based on the latest data in our nightly-refreshed cache.
When does Kestra Medical Technologies, Ltd.'s fiscal year end?
KMTS's fiscal year ends in April. Its most recent annual filing covers the fiscal year ending 2025-04-30.
Where does this data come from?
All figures are computed from Kestra Medical Technologies, Ltd.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.